The primary effect on the proteome of ARID1A-mutated ovarian clear cell carcinoma is downregulation of the mevalonate pathway at the post-transcriptional level

Molecular and Cellular Proteomics

Volumn 15, Issue 11, 2016, Pages 3348-3360

  Goldman, Aaron R ^a   Bitler, Benjamin G ^a   Schug, Zachary ^a   Conejo Garcia, Jose R ^a   Zhang, Rugang ^a   Speicher, David W ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A PROTEIN; CHOLESTEROL; GLYCOGEN; ISOPRENOID; MEVALONIC ACID; PROTEOME; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN;

ARTICLE; CARCINOMA CELL LINE; CHOLESTEROL SYNTHESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ECTOPIC EXPRESSION; GENE MUTATION; GLYCOGEN METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; METABOLISM; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PRENYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; WILD TYPE; ADENOCARCINOMA; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; LIQUID CHROMATOGRAPHY; MUTATION; OVARY TUMOR; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; MUTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROTEOME; TANDEM MASS SPECTROMETRY; TRANSCRIPTION FACTORS;

EID: 84995426673     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M116.062539     Document Type: Article

References (54)

1. Siegel, R. L., Miller, K. D., and Jemal, A. (2016) Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30
2. Itamochi, H., Kigawa, J., and Terakawa, N. (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 99, 653-658
3. Pectasides, D., Pectasides, E., Psyrri, A., and Economopoulos, T. (2006) Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11, 1089-1094
4. Kurman, R. J., and Shih Ie, M. (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27, 151-160
5. Yamaguchi, K., Mandai, M., Oura, T., Matsumura, N., Hamanishi, J., Baba, T., Matsui, S., Murphy, S. K., and Konishi, I. (2010) Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29, 1741-1752
6. Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., Yang, W., Heravi-Moussavi, A., Giuliany, R., Chow, C., Fee, J., Zayed, A., Prentice, L., Melnyk, N., Turashvili, G., Delaney, A. D., Madore, J., Yip, S., Mc-Pherson, A. W., Ha, G., Bell, L., Fereday, S., Tam, A., Galletta, L., Tonin, P. N., Provencher, D., Miller, D., Jones, S. J., Moore, R. A., Morin, G. B., Oloumi, A., Boyd, N., Aparicio, S. A., Shih Ie, M., Mes-Masson, A. M., Bowtell, D. D., Hirst, M., Gilks, B., Marra, M. A., and Huntsman, D. G. (2010) ARID1A mutations in endometriosis-associ-ated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543
7. Jones, S., Wang, T. L., Shih Ie, M., Mao, T. L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Jr, Vogelstein, B., Kinzler, K. W., Velculescu, V. E., and Papadopoulos, N. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231
8. Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., and Getz, G. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501
9. Wang, K., Kan, J., Yuen, S. T., Shi, S. T., Chu, K. M., Law, S., Chan, T. L., Kan, Z., Chan, A. S., Tsui, W. Y., Lee, S. P., Ho, S. L., Chan, A. K., Cheng, G. H., Roberts, P. C., Rejto, P. A., Gibson, N. W., Pocalyko, D. J., Mao, M., Xu, J., and Leung, S. Y. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43, 1219-1223
10. Mamo, A., Cavallone, L., Tuzmen, S., Chabot, C., Ferrario, C., Hassan, S., Edgren, H., Kallioniemi, O., Aleynikova, O., Przybytkowski, E., Malcolm, K., Mousses, S., Tonin, P. N., and Basik, M. (2012) An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31, 2090-2100
11. Helming, K. C., Wang, X., and Roberts, C. W. (2014) Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 26, 309-317
12. Kadoch, C., and Crabtree, G. R. (2015) Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci. Adv. 1, e1500447
13. Chandler, R. L., Brennan, J., Schisler, J. C., Serber, D., Patterson, C., and Magnuson, T. (2013) ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF. Mol. Cell. Biol. 33, 265-280
14. Patsialou, A., Wilsker, D., and Moran, E. (2005) DNA-binding properties of ARID family proteins. Nucleic Acids Res. 33, 66-80
15. Dallas, P. B., Pacchione, S., Wilsker, D., Bowrin, V., Kobayashi, R., and Moran, E. (2000) The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol. Cell. Biol. 20, 3137-3146
16. Nie, Z., Xue, Y., Yang, D., Zhou, S., Deroo, B. J., Archer, T. K., and Wang, W. (2000) A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol. Cell. Biol. 20, 8879-8888
17. Guan, B., Wang, T. L., and Shih Ie, M. (2011) ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 71, 6718-6727
18. Helming, K. C., Wang, X., Wilson, B. G., Vazquez, F., Haswell, J. R., Manchester, H. E., Kim, Y., Kryukov, G. V., Ghandi, M., Aguirre, A. J., Jagani, Z., Wang, Z., Garraway, L. A., Hahn, W. C., and Roberts, C. W. (2014) ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20, 251-254
19. Raab, J. R., Resnick, S., and Magnuson, T. (2015) Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes. PLoS Genet. 11, e1005748
20. Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih Ie, M., Conejo-Garcia, J. R., Spei-cher, D. W., and Zhang, R. (2015) Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231-238
21. Zhai, Y., Kuick, R., Tipton, C., Wu, R., Sessine, M., Wang, Z., Baker, S. J., Fearon, E. R., and Cho, K. R. (2016) Arid1a inactivation in an Apc-and Pten-defective mouse ovarian cancer model enhances epithelial differ-entiation and prolongs survival. J. Pathol. 238, 21-30
22. Vogel, C., and Marcotte, E. M. (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227-232
23. Wiegand, K. C., Hennessy, B. T., Leung, S., Wang, Y., Ju, Z., McGahren, M., Kalloger, S. E., Finlayson, S., Stemke-Hale, K., Lu, Y., Zhang, F., Anglesio, M. S., Gilks, B., Mills, G. B., Huntsman, D. G., and Carey, M. S. (2014) A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 14, 120
24. Beer, L. A., Tang, H. Y., Sriswasdi, S., Barnhart, K. T., and Speicher, D. W. (2011) Systematic discovery of ectopic pregnancy serum biomarkers using 3-D protein profiling coupled with label-free quantitation. J. Pro-teome Res. 10, 1126-1138
25. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372
26. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794-1805
27. Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., and Mann, M. (2014) Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513-2526
28. Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., and Cox, J. (2016) The Perseus computational platform for compre-hensive analysis of (prote)omics data. Nat Methods 13, 731-740
29. Lazar, C., Gatto, L., Ferro, M., Bruley, C., and Burger, T. (2016) Accounting for the Multiple Natures of Missing Values in Label-Free Quantitative Proteomics Data Sets to Compare Imputation Strategies. J. Proteome Res. 15, 1116-1125
30. Berchuck, A., Rodriguez, G., Olt, G., Whitaker, R., Boente, M. P., Arrick, B. A., Clarke-Pearson, D. L., and Bast, R. C., Jr. (1992) Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am. J. Obstet. Gynecol. 166, 676-684
31. Nagaraj, N., Wisniewski, J. R., Geiger, T., Cox, J., Kircher, M., Kelso, J., Paabo, S., and Mann, M. (2011) Deep proteome and transcriptome mapping of a human cancer cell line. Mol. Syst. Biol. 7, 548
32. Geiger, T., Wehner, A., Schaab, C., Cox, J., and Mann, M. (2012) Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol. Cell. Proteomics 11, M111 014050
33. Wang, W., Cote, J., Xue, Y., Zhou, S., Khavari, P. A., Biggar, S. R., Muchardt, C., Kalpana, G. V., Goff, S. P., Yaniv, M., Workman, J. L., and Crabtree, G. R. (1996) Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 15, 5370-5382
34. Goldstein, J. L., and Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature 343, 425-430
35. Buhaescu, I., and Izzedine, H. (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin. Biochem. 40, 575-584
36. Morrison, D. K. (2009) The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 19, 16-23
37. Phan, L., Chou, P. C., Velazquez-Torres, G., Samudio, I., Parreno, K., Huang, Y., Tseng, C., Vu, T., Gully, C., Su, C. H., Wang, E., Chen, J., Choi, H. H., Fuentes-Mattei, E., Shin, J. H., Shiang, C., Grabiner, B., Blonska, M., Skerl, S., Shao, Y., Cody, D., Delacerda, J., Kingsley, C., Webb, D., Carlock, C., Zhou, Z., Hsieh, Y. C., Lee, J., Elliott, A., Ramirez, M., Bankson, J., Hazle, J., Wang, Y., Li, L., Weng, S., Rizk, N., Wen, Y. Y., Lin, X., Wang, H., Wang, H., Zhang, A., Xia, X., Wu, Y., Habra, M., Yang, W., Pusztai, L., Yeung, S. C., and Lee, M. H. (2015) The cell cycle regulator 14-3-3sigma opposes and reverses cancer metabolic repro-gramming. Nat. Commun. 6, 7530
38. Gorai, I., Nakazawa, T., Miyagi, E., Hirahara, F., Nagashima, Y., and Minaguchi, H. (1995) Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol. Oncol. 57, 33-46
39. Berndt, N., Hamilton, A. D., and Sebti, S. M. (2011) Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775-791
40. Clendening, J. W., Pandyra, A., Boutros, P. C., El Ghamrasni, S., Khosravi, F., Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurisica, I., and Penn, L. Z. (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. U.S.A. 107, 15051-15056
41. Thurnher, M., Nussbaumer, O., and Gruenbacher, G. (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res. 18, 3524-3531
42. Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerod, A., Moon, S. H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., Bissell, M. J., Osborne, T. F., Tian, B., Lowe, S. W., Silva, J. M., Borre-sen-Dale, A. L., Levine, A. J., Bargonetti, J., and Prives, C. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258
43. Baandrup, L., Dehlendorff, C., Friis, S., Olsen, J. H., and Kjaer, S. K. (2015) Statin use and risk for ovarian cancer: a Danish nationwide case-control study. Br. J. Cancer 112, 157-161
44. Fathi, A., Pakzad, M., Taei, A., Brink, T. C., Pirhaji, L., Ruiz, G., Sharif Tabe Bordbar, M., Gourabi, H., Adjaye, J., Baharvand, H., and Salekdeh, G. H. (2009) Comparative proteome and transcriptome analyses of embryonic stem cells during embryoid body-based differentiation. Proteomics 9, 4859-4870
45. Sap, K. A., Bezstarosti, K., Dekkers, D. H., van den Hout, M., van Ijcken, W., Rijkers, E., and Demmers, J. A. (2015) Global quantitative proteomics reveals novel factors in the ecdysone signaling pathway in Drosophila melanogaster. Proteomics 15, 725-738
46. Burg, J. S., and Espenshade, P. J. (2011) Regulation of HMG-CoA reductase in mammals and yeast. Prog. Lipid Res. 50, 403-410
47. Jo, Y., and Debose-Boyd, R. A. (2010) Control of cholesterol synthesis through regulated ER-associated degradation of HMG CoA reductase. Crit. Rev. Biochem. Mol. Biol. 45, 185-198
48. Hampton, R. Y., and Bhakta, H. (1997) Ubiquitin-mediated regulation of 3-hydroxy-3-methylglutaryl-CoA reductase. Proc. Natl. Acad. Sci. U.S.A. 94, 12944-12948
49. Ravid, T., Doolman, R., Avner, R., Harats, D., and Roitelman, J. (2000) The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 275, 35840-35847
50. Gill, S., Stevenson, J., Kristiana, I., and Brown, A. J. (2011) Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. Cell Metab. 13, 260-273
51. Sapir, A., Tsur, A., Koorman, T., Ching, K., Mishra, P., Bardenheier, A., Podolsky, L., Bening-Abu-Shach, U., Boxem, M., Chou, T. F., Broday, L., and Sternberg, P. W. (2014) Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging. Proc. Natl. Acad. Sci. U.S.A. 111, E3880-E3889
52. Sharpe, L. J., and Brown, A. J. (2013) Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J. Biol. Chem. 288, 18707-18715
53. Ciechanover, A. (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6, 79-87
54. Hornbeck, P. V., Zhang, B., Murray, B., Kornhauser, J. M., Latham, V., and Skrzypek, E. (2015) PhosphoSitePlus, 2014: mutations, PTMs and reca-librations. Nucleic Acids Res. 43, D512-D520